InflaRx N.V. Gets Positive CHMP Opinion for GOHIBIC®
Ticker: IFRX · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1708688
Sentiment: bullish
Topics: regulatory-approval, pharmaceutical, covid-19
Related Tickers: IFRX
TL;DR
InflaRx N.V. (IFRX) got a green light from EU regulators for its COVID-19 drug GOHIBIC®!
AI Summary
On November 15, 2024, InflaRx N.V. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for GOHIBIC® (vilobelimab) under exceptional circumstances. This recommendation is for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Why It Matters
This positive opinion from the CHMP is a significant step towards potential marketing authorization in Europe for GOHIBIC®, offering a new treatment option for severe COVID-19 patients.
Risk Assessment
Risk Level: medium — While a positive CHMP opinion is good news, it's not final marketing authorization, and the drug's commercial success and patient adoption remain to be seen.
Key Players & Entities
- InflaRx N.V. (company) — The company filing the report and announcing the news.
- GOHIBIC® (drug) — The drug for which a positive CHMP opinion was received.
- vilobelimab (drug) — The active ingredient in GOHIBIC®.
- Committee for Medicinal Products for Human Use (CHMP) (company) — The regulatory body that issued the positive opinion.
- European Medicines Agency (company) — The overarching regulatory agency.
- November 15, 2024 (date) — The date of the announcement.
FAQ
What is the specific recommendation from the CHMP regarding GOHIBIC®?
The CHMP adopted a positive opinion recommending marketing authorization for GOHIBIC® (vilobelimab) under exceptional circumstances.
What condition is GOHIBIC® intended to treat?
GOHIBIC® is intended for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
What is the significance of a 'positive opinion' from the CHMP?
A positive opinion from the CHMP is a recommendation for marketing authorization, a crucial step before the drug can be approved for sale in the European Union.
Under what specific circumstances is GOHIBIC® being considered for marketing authorization?
GOHIBIC® is being considered for marketing authorization under exceptional circumstances.
What is the filing date of this Form 6-K?
This Form 6-K was filed on November 15, 2024.
Filing Stats: 303 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-11-15 08:04:37
Filing Documents
- ef20038701_6k.htm (6-K) — 10KB
- ef20038701_ex99-1.htm (EX-99.1) — 17KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-047029.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: November 15, 2024 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer